US 8,524,901 B2Granted

Compositions and methods for inhibition of the JAK pathway

AssigneeRigel Pharmaceuticals, Inc.

InventorsHui Li, Yan Chen, Rajinder Singh

Life of this patent

Estimating the term…

Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Claims2

Dependent claims

A compound, or pharmaceutically acceptable salt thereof, wherein the compound is N2-(3-methoxy-5-trifluoromethyl)phenyl-5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]-2,4-pyrimidinediamine.

Dependencies are inferred from the claim text.

Facts

Application: 13/241,037Filed 22 Sep 2011 · continuation
Priority: 23 Jan 2009
Published: US 2012/0010407 A112 Jan 2012
Granted: 3 Sep 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification45 codes

C07D 413/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61K 31/155
Amines: amidines , e.g. guanidine , isourea , isothiourea
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol

Family

Application61/147,059Us provisional application · filed 23 Jan 2009
Application61/241,630Us provisional application · filed 11 Sep 2009
Application12/692,493Parent of this continuation · filed 22 Jan 2010
US 2012/0010407 A1Pre-grant publication · published 12 Jan 2012
US 8,324,200 B2Parent of this continuation
US 2010/0190770 A1Published application
US 8,524,901 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results